AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17884363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine-atropine stress echocardiography (DASE)
Number of subjects: 199
Study 17884363 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiographic exercise testing (EET)
Number of subjects: 199
Study 14720527 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission troponin T (tnT) >/=0.1 microg/l (n=116)
Number of subjects: 516
Study 14720527 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment resolution <50% (n=301)
Number of subjects: 516
Study 14720527 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tnT elevation and no ST-segment resolution
Number of subjects: 516
Study 12140636 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐min course with lecture, video, and individual proctoring
Number of subjects: 17
Study 12140636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 17
Study 12140636 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing assist device
Number of subjects: 17
Study 12140636 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laparoscopic instruments
Number of subjects: 17
Study 9709844 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative talocalcaneal (TC) angle
Number of subjects: 62
Study 9709844 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Rating System (FRS) of Laaveg and Ponseti
Number of subjects: 62
Study 9709844 — intervention group
Group type: EXPERIMENTAL
Intervention: Talocalcaneal angle (AP), talonavicular angle (AP and lateral), calcaneometatarsal V angle
Number of subjects: 62
Study 8295050 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (MS)
Number of subjects: 68
Study 8295050 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 68
Study 2732524 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol neurolytic block
Number of subjects: 28
Study 2732524 — intervention group
Group type: COMPARATOR
Intervention: Cryogenic block
Number of subjects: 28
Study 2732524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 28
Study 31220200 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person 60-min incontinence self-management workshop
Number of subjects: 909
Study 31220200 — intervention group
Group type: COMPARATOR
Intervention: Control healthy ageing workshop
Number of subjects: 909
Study 28216660 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR (Fludarabine, Cyclophosphamide, Rituximab)
Number of subjects: 215
Study 28216660 — intervention group
Group type: COMPARATOR
Intervention: FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab)
Number of subjects: 215
Study 26033641 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg
Number of subjects: 0
Study 26033641 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg
Number of subjects: 0
Study 26033641 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 2.5 mg
Number of subjects: 0
Study 26033641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26033641 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg and 15 mg
Number of subjects: 0
Study 23218449 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized asthma detection system
Number of subjects: 704
Study 23218449 — intervention group
Group type: COMPARATOR
Intervention: Standard processes for control patients
Number of subjects: 704
Study 21792695 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute survival framing format
Number of subjects: 2552
Study 21792695 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute mortality framing format
Number of subjects: 2552
Study 21792695 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative mortality reduction framing format
Number of subjects: 2552
Study 21792695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully informed condition
Number of subjects: 2552
Study 21792695 — intervention group
Group type: COMPARATOR
Intervention: Comparison to fully informed condition
Number of subjects: 2552
Study 18987880 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct experience condition (participants saw simple events directly perceived)
Number of subjects: 0
Study 18987880 — intervention group
Group type: COMPARATOR
Intervention: Indirectly conveyed information conditions (information about the object, kind of event, or both were verbally conveyed)
Number of subjects: 0
Study 16079172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (etanercept 25 mg twice weekly + methotrexate up to 20 mg weekly)
Number of subjects: 682
Study 16079172 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) up to 20 mg weekly
Number of subjects: 682
Study 16079172 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 682
Study 16079172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 682
Study 16079172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy and etanercept
Number of subjects: 682
Study 12545341 — intervention group
Group type: EXPERIMENTAL
Intervention: basiliximab 1 x 40-mg group
Number of subjects: 202
Study 12545341 — intervention group
Group type: COMPARATOR
Intervention: basiliximab 2 x 20-mg group
Number of subjects: 202
Study 10924561 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (180 mL of iopromide containing 370 mg of iodine per milliliter)
Number of subjects: 102
Study 10924561 — intervention group
Group type: COMPARATOR
Intervention: Group B (180 mL of iopromide containing 300 mg of iodine per milliliter)
Number of subjects: 102
Study 10924561 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 102
Study 8831332 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 micrograms/kg bolus followed by infusion at 2 micrograms.kg-1.h-1)
Number of subjects: 6
Study 8831332 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms/kg bolus followed by infusion at 4 micrograms.kg-1.h-1)
Number of subjects: 6
Study 8831332 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 1486258 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol 2%
Number of subjects: 50
Study 1486258 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol 2% suspended with liposomes (FAT-MLVs)
Number of subjects: 50
Study 3973383 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 micrograms HA of trivalent surface-antigen influenza virus vaccine
Number of subjects: 0
Study 3973383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3678549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (oral and intradermal administration)
Number of subjects: 0
Study 3678549 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam, piroxicam, and benoxaprofen (10-40 micrograms/ml) in vitro
Number of subjects: 0
Study 29220876 — intervention group
Group type: EXPERIMENTAL
Intervention: New HFC (FIBRYGA, Octapharma AG)
Number of subjects: 22
Study 29220876 — intervention group
Group type: COMPARATOR
Intervention: Control (Haemocomplettan® P/RiaSTAP™, CSL Behring GmbH)
Number of subjects: 22
Study 28700496 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming‐plus‐subliminal reward stimuli (experimental)
Number of subjects: 50
Study 28700496 — intervention group
Group type: COMPARATOR
Intervention: Subliminal priming‐plus‐supraliminal reward stimuli (control)
Number of subjects: 50
Study 25813447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg once daily) for 8 to 16 weeks
Number of subjects: 25
Study 23649780 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Bearing (WB) protocol
Number of subjects: 38
Study 23649780 — intervention group
Group type: COMPARATOR
Intervention: Non-Weight Bearing (NWB) protocol
Number of subjects: 38
Study 23649780 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected legs (both groups)
Number of subjects: 38
Study 23649780 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock absorption (both groups)
Number of subjects: 38
Study 20233522 — intervention group
Group type: EXPERIMENTAL
Intervention: C-length guided method
Number of subjects: 637
Study 20233522 — intervention group
Group type: COMPARATOR
Intervention: 15-cm guided method
Number of subjects: 637
Study 18185107 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS (continuous Theta Burst Stimulation)
Number of subjects: 0
Study 18185107 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 16756783 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 100
Study 16756783 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 100
Study 14761115 — intervention group
Group type: EXPERIMENTAL
Intervention: GCF IFN-gamma levels at progressing sites
Number of subjects: 33
Study 14761115 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measurements (gingival index, plaque index, bleeding on probing, probing depth, attachment loss)
Number of subjects: 33
Study 14761115 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of periodontitis
Number of subjects: 33
Study 11025394 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyto Hypophyson L
Number of subjects: 67
Study 11025394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 8979740 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 200
Study 8979740 — intervention group
Group type: COMPARATOR
Intervention: Control (no amiodarone therapy)
Number of subjects: 200
Study 1632533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg IV)
Number of subjects: 31
Study 1632533 — intervention group
Group type: COMPARATOR
Intervention: Morphine (5 mg IV)
Number of subjects: 31
Study 1632533 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (10 mg)
Number of subjects: 31
Study 1632533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6152615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 6152615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 6152615 — intervention group
Group type: COMPARATOR
Intervention: Common emulsion antacid
Number of subjects: 0
Study 30794574 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased font size
Number of subjects: 6255
Study 30794574 — intervention group
Group type: EXPERIMENTAL
Intervention: Describing indications for use on the label
Number of subjects: 6255
Study 30794574 — intervention group
Group type: EXPERIMENTAL
Intervention: Describing contraindications on the label
Number of subjects: 6255
Study 30794574 — intervention group
Group type: EXPERIMENTAL
Intervention: Highlighting the expiration date on the label
Number of subjects: 6255
Study 30794574 — intervention group
Group type: EXPERIMENTAL
Intervention: New simulated package design with increased font size, color to highlight concentration, and contrast between font color and background
Number of subjects: 6255
Study 30794574 — intervention group
Group type: COMPARATOR
Intervention: Standard design
Number of subjects: 6255
Study 30794574 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall readability and comprehensibility of medication labels
Number of subjects: 6255
Study 30080980 — intervention group
Group type: EXPERIMENTAL
Intervention: Special diets
Number of subjects: 32
Study 30080980 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 32
Study 27106162 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 84
Study 27106162 — intervention group
Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 84
Study 25171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel 2%
Number of subjects: 260
Study 25171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel 3.5%
Number of subjects: 260
Study 25171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel 5%
Number of subjects: 260
Study 25171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel 8%
Number of subjects: 260
Study 25171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel 12%
Number of subjects: 260
Study 25171074 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 260
Study 22323482 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative conditioning
Number of subjects: 832
Study 22323482 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced‐intensity conditioning (RIC)
Number of subjects: 832
Study 20616293 — intervention group
Group type: EXPERIMENTAL
Intervention: Family medicine setting (n = 116)
Number of subjects: 847
Study 20616293 — intervention group
Group type: COMPARATOR
Intervention: Specialized reproductive health clinics (n = 731)
Number of subjects: 847
Study 17765245 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg
Number of subjects: 50
Study 17765245 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide 80 mg
Number of subjects: 50
Study 17765245 — intervention group
Group type: COMPARATOR
Intervention: Gliclazone 80 mg
Number of subjects: 50
Study 15661116 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT + active rTMS
Number of subjects: 22
Study 15661116 — intervention group
Group type: COMPARATOR
Intervention: ECT + sham rTMS
Number of subjects: 22
Study 15661116 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT (both groups)
Number of subjects: 22
Study 12492181 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication (cure)
Number of subjects: 1165
Study 12492181 — intervention group
Group type: COMPARATOR
Intervention: Persistent H. pylori infection (control)
Number of subjects: 1165
Study 9665113 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU for children > 1 year; 100,000 IU for infants)
Number of subjects: 687
Study 9665113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 9665113 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 687
Study 19496272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily, commencing at least 2 weeks before planned PICA
Number of subjects: 730
Study 2668397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymomodulin (120 mg/day)
Number of subjects: 19
Study 2668397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 326332 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar injection of triamcinolone
Number of subjects: 0
Study 326332 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30001171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (SEL+)
Number of subjects: 40
Study 30001171 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (SEL-)
Number of subjects: 40
Study 30360536 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 436
Study 30360536 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating (HE)
Number of subjects: 436
Study 30360536 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 436
Study 30360536 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating (HE) and Physical Activity (PA)
Number of subjects: 436
Study 30360536 — intervention group
Group type: EXPERIMENTAL
Intervention: GWG over the median at 35⁻37 weeks
Number of subjects: 436
Study 26519191 — intervention group
Group type: EXPERIMENTAL
Intervention: Velpatasvir (VEL; GS‐5816)
Number of subjects: 0
Study 24790703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise 5 days a week for 6 months
Number of subjects: 71
Study 24790703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tai Chi)
Number of subjects: 71
Study 22142020 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg x kg(‐1) body mass
Number of subjects: 16
Study 22142020 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg x kg(‐1) body mass
Number of subjects: 16
Study 22142020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20112481 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 105
Study 20112481 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acupuncture
Number of subjects: 105
Study 20112481 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (abdominal acupuncture plus conventional acupuncture)
Number of subjects: 105
Study 17451415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD) + bioactive glass (BG)
Number of subjects: 25
Study 17451415 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix protein derivative (EMD) alone
Number of subjects: 25
Study 15237003 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy phytoestrogens (150 mg of isoflavones per day) for 5 years
Number of subjects: 376
Study 15237003 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 5 years
Number of subjects: 376
Study 12564661 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care with atorvastatin 10-80 mg
Number of subjects: 1600
Study 12564661 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1600
Study 12564661 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care with atorvastatin 10-20 mg
Number of subjects: 1600
Study 9173270 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 1138
Study 9173270 — intervention group
Group type: COMPARATOR
Intervention: Accelerated thrombolytic therapy with recombinant tissue plasminogen activator (t-PA)
Number of subjects: 1138
Study 9173270 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty with heparin
Number of subjects: 1138
Study 9173270 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty with hirudin
Number of subjects: 1138
Study 7513879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode A
Number of subjects: 65
Study 7513879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode B
Number of subjects: 65
Study 7513879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode C
Number of subjects: 65
Study 7513879 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ATP
Number of subjects: 65
Study 3588512 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide administered as a bolus injection of 150 mg over 5 min.
Number of subjects: 7
Study 3588512 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide administered as a bolus injection of 150 mg over 20 min.
Number of subjects: 7
Study 3588512 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide administered over 5 min.
Number of subjects: 7
Study 3588512 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide administered over 20 min.
Number of subjects: 7
Study 29926307 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy with modified D2 lymphadenectomy
Number of subjects: 0
Study 29926307 — intervention group
Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 0
Study 28072761 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent chest X-ray
Number of subjects: 255
Study 28072761 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 255
Study 25851062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (dosage and duration not specified)
Number of subjects: 97
Study 25851062 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (intravenous unfractionated heparin followed by warfarin)
Number of subjects: 97
Study 23086589 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Care intervention
Number of subjects: 82
Study 23086589 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 82
Study 21094670 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic blue light exposure for 60 min
Number of subjects: 20
Study 21094670 — intervention group
Group type: COMPARATOR
Intervention: Monochromatic red light exposure for 60 min
Number of subjects: 20
Study 18501867 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally effective health care (CEHC) curriculum
Number of subjects: 91
Study 16569468 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-self assessment/provider reminder tool (A/R)
Number of subjects: 0
Study 16569468 — intervention group
Group type: COMPARATOR
Intervention: Exercise reminder (Control)
Number of subjects: 0
Study 16569468 — intervention group
Group type: COMPARATOR
Intervention: Control (Exercise reminder)
Number of subjects: 0
Study 12660530 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/RTV) 800 mg/100 mg q12h
Number of subjects: 323
Study 12660530 — intervention group
Group type: COMPARATOR
Intervention: Indinavir (IDV) 800 mg q8h
Number of subjects: 323
Study 11908356 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation dentifrice containing 5.0% potassium nitrate and 0.454% stannous fluoride in a silica base
Number of subjects: 66
Study 11908356 — intervention group
Group type: COMPARATOR
Intervention: Commercially available nondesensitizing control dentifrice (Colgate Winterfresh Gel)
Number of subjects: 66
Study 8704665 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health services (skilled nursing services)
Number of subjects: 0
Study 8704665 — intervention group
Group type: COMPARATOR
Intervention: No home health services
Number of subjects: 0
Study 7877829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat Mobilisation System (FMS) - bandaging with elasticated bandages soaked in active solution able to lower body temperature by 2-3 degrees C
Number of subjects: 109
Study 7877829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat Mobilisation System (FMS)
Number of subjects: 109
Study 3356931 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple occlusal adjustment
Number of subjects: 22
Study 3356931 — intervention group
Group type: COMPARATOR
Intervention: Mock adjustment (placebo)
Number of subjects: 22
Study 30788810 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (glucose-insulin-potassium)
Number of subjects: 100
Study 30788810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29655779 — intervention group
Group type: EXPERIMENTAL
Intervention: VERSAFIBE™ 2470 resistant starch muffin top (11.6 g TDF)
Number of subjects: 28